Novavax Inc.

6.00
0.00 (0.00%)
At close: Apr 02, 2025, 3:59 PM
5.88
-2.08%
After-hours: Apr 02, 2025, 07:59 PM EDT

Company Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.

The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics.

It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate.

Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax Inc.
Novavax Inc. logo
Country United States
IPO Date Dec 5, 1995
Industry Biotechnology
Sector Healthcare
Employees 952
CEO John Charles Jacobs M.B.A.

Contact Details

Address:
21 Firstfield Road
Gaithersburg, Maryland
United States
Website https://www.novavax.com

Stock Details

Ticker Symbol NVAX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001000694
CUSIP Number 670002401
ISIN Number US6700024010
Employer ID 22-2816046
SIC Code 2836

Key Executives

Name Position
John Charles Jacobs M.B.A. President, Chief Executive Officer & Director
James Patrick Kelly C.F.A. Executive Vice President, Chief Financial Officer & Treasurer
John Joseph Trizzino B.S., M.B.A. President & Chief Operating Officer
Mark Casey Executive Vice President, Chief Legal Officer & Corporate Secretary
Richard P. Crowley Executive Vice President & Chief Operating Officer
Dr. Henrietta Ukwu FACP FRAPS, M.D. Executive Vice President & Chief Regulatory Officer
Erika S. Trahan Associate Director of Investor & Public Relations
Ian J. Watkins Executive Vice President & Chief Human Resources Officer
Silvia Taylor M.B.A. Executive Vice President and Chief Corporate Affairs & Advocacy Officer
Troy Morgan Esq., J.D. Senior Vice President, Deputy General Counsel & Chief Compliance Officer

Latest SEC Filings

Date Type Title
Mar 12, 2025 4 Filing
Mar 12, 2025 3 Filing
Mar 11, 2025 8-K Current Report
Mar 11, 2025 4 Filing
Mar 11, 2025 4 Filing
Mar 11, 2025 8-K Current Report
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing